Clovis Oncology Announces 2018 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
Clovis Oncology (CLVS) Pushes to Highs Following Results; Still Seen as Valuable Takeover Target
February 27, 2019 1:27 PM ESTClovis Oncology (NASDAQ: CLVS) pushes to highs following results. Shares are up 18%. Analysts continue to see the company as an attractive takeover target.
Gabelli's Jing He commented, "We believe Rubraca is a valuable asset with potential in additional tumor types. However, with... More
Clovis Oncology (CLVS) PT Raised to $33 at RBC Capital
February 27, 2019 6:48 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Clovis Oncology (NASDAQ: CLVS) to $33.00 (from $29.00) while maintaining a Outperform rating.
While no 2019 guidance, they like the setup for beats versus the Street for the year ahead.
... MoreClovis Oncology (CLVS) Misses Q4 EPS by 15c
February 26, 2019 8:05 AM ESTClovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($1.88), $0.15 worse than the analyst estimate of ($1.73). Revenue for the quarter came in at $30.4 million versus the consensus estimate of $26.91 million.
For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.
... More